First patient dosed in the Phase 1, first-in-human study of LAVA-1266, marking a significant milestone for the company. LAVA-1266 has demonstrated a strong preclinical safety and efficacy profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback